Cassava Sciences (SAVA) PT Raised to 'Street High' $80 at Maxim Group

February 16, 2021 8:09 AM EST
Get Alerts SAVA Hot Sheet
Price: $34.60 +7.62%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 24 | New: 32
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Maxim Group analyst Jason McCarthy raised the price target on Cassava Sciences (NASDAQ: SAVA) to $80.00 (from $14.00) while maintaining a Buy rating after the company announced the first set of cognition and behavior data from the P2b extension study of simufilam in mild-moderate Alzheimer's disease (AD).

The analyst commented, "The space is shifting, and SAVA's simufilam is about as advanced as any asset in this new wave of AD therapeutics. The 6-month cog data was the start. The 9-month and 12-month cog data are next, as are two phase 3s (even one with a 6-month end point, unheard of in AD). We break it down below. We have lowered our discount rate to 20%, from 30%, and use a 70% risk adjustment (unchanged), which serves to increase our price target to $80, from $14."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, Hot Comments

Related Entities

Maxim Group